121 related articles for article (PubMed ID: 35342938)
41. Stem cells, immortality, and the evolution of metastatic properties in breast cancer: telomere maintenance mechanisms and metastatic evolution.
Robinson NJ; Taylor DJ; Schiemann WP
J Cancer Metastasis Treat; 2019; 5():. PubMed ID: 31440584
[TBL] [Abstract][Full Text] [Related]
42. Telomere fusion threshold identifies a poor prognostic subset of breast cancer patients.
Simpson K; Jones RE; Grimstead JW; Hills R; Pepper C; Baird DM
Mol Oncol; 2015 Jun; 9(6):1186-93. PubMed ID: 25752197
[TBL] [Abstract][Full Text] [Related]
43. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
44. Telomere Trimming and DNA Damage as Signatures of High Risk Neuroblastoma.
Yu EY; Cheung IY; Feng Y; Rabie MO; Roboz GJ; Guzman ML; Cheung NV; Lue NF
Neoplasia; 2019 Jul; 21(7):689-701. PubMed ID: 31128432
[TBL] [Abstract][Full Text] [Related]
45. Telomere dysfunction, genome instability and cancer.
Cheung AL; Deng W
Front Biosci; 2008 Jan; 13():2075-90. PubMed ID: 17981693
[TBL] [Abstract][Full Text] [Related]
46. Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.
Williams C; Brunskill S; Altman D; Briggs A; Campbell H; Clarke M; Glanville J; Gray A; Harris A; Johnston K; Lodge M
Health Technol Assess; 2006 Sep; 10(34):iii-iv, ix-xi, 1-204. PubMed ID: 16959170
[TBL] [Abstract][Full Text] [Related]
47. An integrative pan-cancer investigation reveals common genetic and transcriptional alterations of AMPK pathway genes as important predictors of clinical outcomes across major cancer types.
Chang WH; Lai AG
BMC Cancer; 2020 Aug; 20(1):773. PubMed ID: 32807122
[TBL] [Abstract][Full Text] [Related]
48. Genome rearrangements associated with aberrant telomere maintenance.
Bhargava R; Fischer M; O'Sullivan RJ
Curr Opin Genet Dev; 2020 Feb; 60():31-40. PubMed ID: 32145504
[TBL] [Abstract][Full Text] [Related]
49. Changes in the Expression of Pre-Replicative Complex Genes in hTERT and ALT Pediatric Brain Tumors.
Idilli AI; Pagani F; Kerschbamer E; Berardinelli F; Bernabé M; Cayuela ML; Piazza S; Poliani PL; Cusanelli E; Mione MC
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32331249
[No Abstract] [Full Text] [Related]
50. Telomere length variation in tumor cells and cancer-associated fibroblasts: potential biomarker for hepatocellular carcinoma.
Ma LJ; Wang XY; Duan M; Liu LZ; Shi JY; Dong LQ; Yang LX; Wang ZC; Ding ZB; Ke AW; Cao Y; Zhang XM; Zhou J; Fan J; Gao Q
J Pathol; 2017 Dec; 243(4):407-417. PubMed ID: 28833123
[TBL] [Abstract][Full Text] [Related]
51. Alternative Lengthening of Telomeres (ALT) in Tumors and Pluripotent Stem Cells.
Zhao S; Wang F; Liu L
Genes (Basel); 2019 Dec; 10(12):. PubMed ID: 31835618
[TBL] [Abstract][Full Text] [Related]
52. Evolutionary hypothesis of telomere length in primary breast cancer and brain tumour patients: a tracer for genomic-tumour heterogeneity and instability.
Mehdipour P; Kheirollahi M; Mehrazin M; Kamalian N; Atri M
Cell Biol Int; 2011 Sep; 35(9):915-25. PubMed ID: 21385157
[TBL] [Abstract][Full Text] [Related]
53. Telomere length-related signature as a novel biomarker of prognosis and immune response in non-small cell lung cancer.
Liu XG; Li M; Mai SJ; Cai RJ
Eur Rev Med Pharmacol Sci; 2022 Feb; 26(4):1304-1319. PubMed ID: 35253187
[TBL] [Abstract][Full Text] [Related]
54. Targeting homologous recombination and telomerase in Barrett's adenocarcinoma: impact on telomere maintenance, genomic instability and tumor growth.
Lu R; Pal J; Buon L; Nanjappa P; Shi J; Fulciniti M; Tai YT; Guo L; Yu M; Gryaznov S; Munshi NC; Shammas MA
Oncogene; 2014 Mar; 33(12):1495-505. PubMed ID: 23604115
[TBL] [Abstract][Full Text] [Related]
55. Telomere maintenance in interplay with DNA repair in pathogenesis and treatment of colorectal cancer.
Tomasova K; Kroupa M; Forsti A; Vodicka P; Vodickova L
Mutagenesis; 2020 Jul; 35(3):261-271. PubMed ID: 32083302
[TBL] [Abstract][Full Text] [Related]
56. Telomere dysfunction in aging and cancer.
Gilley D; Tanaka H; Herbert BS
Int J Biochem Cell Biol; 2005 May; 37(5):1000-13. PubMed ID: 15743674
[TBL] [Abstract][Full Text] [Related]
57. NBS1 deficiency promotes genome instability by affecting DNA damage signaling pathway and impairing telomere integrity.
Hou YY; Toh MT; Wang X
Cell Biochem Funct; 2012 Apr; 30(3):233-42. PubMed ID: 22161642
[TBL] [Abstract][Full Text] [Related]
58. The Landscape of the Tumor Microenvironment in Skin Cutaneous Melanoma Reveals a Prognostic and Immunotherapeutically Relevant Gene Signature.
Zhou S; Sun Y; Chen T; Wang J; He J; Lyu J; Shen Y; Chen X; Yang R
Front Cell Dev Biol; 2021; 9():739594. PubMed ID: 34660598
[TBL] [Abstract][Full Text] [Related]
59. A 12-gene genomic instability signature predicts clinical outcomes in multiple cancer types.
Mettu RK; Wan YW; Habermann JK; Ried T; Guo NL
Int J Biol Markers; 2010; 25(4):219-28. PubMed ID: 21161944
[TBL] [Abstract][Full Text] [Related]
60. Comprehensive Characterization of RNA Processing Factors in Gastric Cancer Identifies a Prognostic Signature for Predicting Clinical Outcomes and Therapeutic Responses.
Lou S; Meng F; Yin X; Zhang Y; Han B; Xue Y
Front Immunol; 2021; 12():719628. PubMed ID: 34413861
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
